Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Anaphylaxis Clinical Care Pathway: Incorporating Intranasal Epinephrine (Adrenaline)

  • Timothy E. Dribin
  • , Brad Sobolewski
  • , Ronna L. Campbell
  • , Paul J. Turner
  • , Lene H. Garvey
  • , Jasmeet Soar
  • , Julie Wang
  • , Marcus S. Shaker
  • , Adam T. Fox
  • , Sarayna S. McGuire
  • , Kenneth A. Michelson
  • , David Schnadower
  • , Graham Roberts
  • , Waleed Alqurashi
  • , Moshe Ben-Shoshan
  • , David C. Brousseau
  • , Dianne E. Campbell
  • , Andrew T. Clark
  • , Antoine Deschildre
  • , Katie Frith
  • Mattia Giovannini, Gideon Lack, Antonella Muraro, Mark I. Neuman, Nandinee Patel, Guillaume Pouessel, Kristina Rueter, Nicholas Sargant, Peter Smith, Susan Waserman, Gary Wing Kin Wong, Margitta Worm, Hugh A. Sampson
  • Cincinnati Children's Hospital Medical Center
  • University of Cincinnati
  • Mayo Clinic Rochester, MN
  • Imperial College London
  • University of Copenhagen
  • Southmead Hospital Bristol
  • Kravis Children's Hospital
  • Icahn School of Medicine at Mount Sinai
  • Dartmouth-Hitchcock Medical Center
  • Dartmouth College
  • Evelina London Children's Hospital
  • Children's Memorial Hospital
  • University of Southampton
  • Isle of Wight NHS Trust
  • University Hospital Southampton NHS Foundation Trust
  • University of Ottawa
  • McGill University
  • Thomas Jefferson University
  • University of Sydney
  • National Allergy Centre of Excellence (NACE)
  • Cambridge University Hospitals NHS Foundation Trust
  • Université de Lille
  • Sydney Children's Hospital
  • University of New South Wales
  • Meyer Children's Hospital IRCCS
  • University of Florence
  • King's College London
  • Azienda Ospedaliera di Padova
  • Boston Children's Hospital
  • Centre Hospitalier de Roubaix
  • Perth Children's Hospital
  • University of Western Australia
  • University Hospitals Bristol and Weston NHS Foundation Trust
  • Griffith University Queensland
  • Queensland Allergy Services Private Practice
  • St. Joseph's Healthcare Hamilton
  • McMaster University
  • Chinese University of Hong Kong
  • Charité – Universitätsmedizin Berlin

Producción científica › revisión exhaustiva

Resumen

Health care providers across settings must be trained to manage anaphylaxis by (1) removing the offending allergen if still present; (2) positioning the patient with legs elevated, and if respiratory distress is present, allow the patient to sit upright with legs extended and elevated; (3) immediately administering epinephrine (adrenaline) intramuscularly (IM) or intranasally (IN) every 5 to 15 minutes for persistent anaphylaxis; and (4) optimizing airway, breathing, and cardiovascular (ABC) resuscitation. This may include supplemental oxygen, noninvasive or invasive positive-pressure ventilation, and intravenous fluid resuscitation. For life-threatening or refractory presentations, (5) IM/IN epinephrine should be administered every 5 minutes while addressing ABC derangements; this includes aggressive intravenous fluid resuscitation for patients in anaphylactic shock. Providers may continue IM or IN epinephrine or switch to the other, as both routes are considered equally efficacious based on pharmacokinetic data. An intravenous epinephrine infusion should be prepared for patients with persistent anaphylaxis after 2 doses of IM/IN epinephrine and initiated after the third dose, or earlier at the provider's discretion. In settings without epinephrine infusions, repeat IM/IN epinephrine should be administered every 5 minutes, along with other ABC interventions, and the patient should be transferred quickly to a setting equipped to provide advanced resuscitative care.

Idioma originalEnglish
PublicaciónJournal of Allergy and Clinical Immunology: In Practice
DOI
EstadoAccepted/In press - 2026

Huella

Profundice en los temas de investigación de 'Anaphylaxis Clinical Care Pathway: Incorporating Intranasal Epinephrine (Adrenaline)'. En conjunto forman una huella única.

Citar esto